Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Long-term Potentiation01:35

Long-term Potentiation

59.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
59.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses.

European journal of immunology·2025
Same author

German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise.

Multiple sclerosis and related disorders·2022
Same author

Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies.

Multiple sclerosis and related disorders·2022
Same author

Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis.

Multiple sclerosis and related disorders·2021
Same author

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders.

Neurological research and practice·2021
Same author

Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[From feeblemindedness to intellectual deficiency : Some comments from the forensic-psychiatric perspective on the replacement of the juridical term in the German Criminal Code (the criminal liability paragraph 20 StGB)].

Der Nervenarzt·2026
See all related articles

Related Experiment Video

Updated: Mar 13, 2026

Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.5K

[Progressive multifocal leukoencephalopathy].

C Warnke1, M P Wattjes2, O Adams3

  • 1Klinik für Neurologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland. warnke@uni-duesseldorf.de.

Der Nervenarzt
|October 13, 2016
PubMed
Summary
This summary is machine-generated.

Progressive multifocal leukoencephalopathy (PML), a brain disease caused by the JC polyomavirus (JCPyV), is increasingly relevant in immunosuppressed patients. This review covers PML biology, diagnostics, and management strategies.

Keywords:
Cerebrospinal fluidJC polyomavirusMultiple sclerosisNatalizumabPML

More Related Videos

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

19.0K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K

Related Experiment Videos

Last Updated: Mar 13, 2026

Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.5K
Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

19.0K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K

Area of Science:

  • Neurovirology
  • Immunology
  • Neurology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare but serious opportunistic infection of the brain.
  • It is caused by the JC polyomavirus (JCPyV), typically in immunocompromised individuals.
  • The incidence of PML has risen due to its association with certain biologic therapies, including natalizumab for multiple sclerosis.

Purpose of the Study:

  • To provide a comprehensive overview of the biology and pathogenesis of PML.
  • To highlight the importance of cerebrospinal fluid (CSF) diagnostics in PML detection.
  • To discuss current PML case definitions, risk management, and therapeutic options.

Main Methods:

  • Review of published literature on JC polyomavirus and PML.
  • Analysis of diagnostic approaches, particularly CSF analysis.
  • Synthesis of current recommendations for risk management, therapy, and prevention.

Main Results:

  • JCPyV infects oligodendrocytes, leading to demyelination in PML.
  • CSF analysis is crucial for accurate and timely PML diagnosis.
  • Risk stratification and monitoring are essential for patients on immunosuppressive therapies.

Conclusions:

  • Understanding PML pathogenesis is key to developing effective treatments.
  • Early diagnosis via CSF testing improves patient outcomes.
  • Multidisciplinary management strategies are necessary for PML prevention and treatment.